G Paoletti, M Casini, L Malvezzi, F Pirola, E Russo, E Nappi, G Q Muci, C Montagna, M R Messina, S Ferri, F Racca, D Lamacchia, G Cataldo, F Puggioni, A De Virgilio, F Ferreli, G Mercante, G Spriano, G W Canonica, E Heffler
BACKGROUND AND OBJECTIVE: Dupilumab, an anti-IL-4 receptor a monoclonal antibody, was recently approved for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) and moderate-to-severe asthma. Onset of its clinical effects is rapid. CRSwNP is characterized by extended type 2 inflammatory involvement that can be assessed using extended nitric oxide analysis. We investigated whether dupilumab was associated with a rapid improvement in extended nitric oxide parameters, lung function, and clinical outcomes in patients with CRSwNP...
December 2023: Journal of Investigational Allergology & Clinical Immunology